{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T07:50:34Z","timestamp":1791532234982,"version":"4.3.4"},"reference-count":33,"publisher":"SAGE Publications","issue":"11","license":[{"start":{"date-parts":[[2025,9,2]],"date-time":"2025-09-02T00:00:00Z","timestamp":1756771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Disease","doi-asserted-by":"crossref","award":["K23AI157875"],"award-info":[{"award-number":["K23AI157875"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"crossref","award":["5UM1AI164560"],"award-info":[{"award-number":["5UM1AI164560"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"crossref","award":["INV-002707"],"award-info":[{"award-number":["INV-002707"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000025","name":"National Institute of Mental Health","doi-asserted-by":"crossref","award":["R01-MH126768"],"award-info":[{"award-number":["R01-MH126768"]}],"id":[{"id":"10.13039\/100000025","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["AIDS Research and Human Retroviruses"],"published-print":{"date-parts":[[2025,12,1]]},"abstract":"<jats:p>HIV cure-related clinical research studies often include analytical treatment interruptions (ATIs), in which participants pause antiretroviral treatment (ART). During ATIs, researchers closely monitor laboratory values and adverse events. We assessed and compared the perspectives of two distinct groups of participants: HIV noncontrollers and controllers in a San Francisco-based ATI study focused on identifying biomarkers predicting HIV viral rebound. Data were collected from 2021 to 2024 over five study time points to assess motivations, understanding of the study, decisional regret, and partner protections. All participants (n = 16) endorsed the goal of helping advance HIV research as a motivator, about half were also driven by interest in their body\u2019s response to the ATI, and some indicated monetary compensation as a key motivator. Most participants (6 of 10 noncontrollers and 4 of 6 controllers) did not view personal health benefit as a primary study goal. All understood the option for an extended ATI if they had not met ART restart criteria after 28 days. At the study\u2019s onset, all sexually active participants (n = 14) were informed about the risk of transmission to sex partners and the need for partner protections during ATIs. Among noncontrollers, 2 of 5 reported using condoms, being abstinent or partner use of pre-exposure prophylaxis (PrEP) during sexual activity. Among controllers, 3 of 5 reported sexual activity: one with a partner on PrEP, one with a partner on ART, and one using other protection methods. Decisional regret about study participation, measured on a scale of 0\u2013100, was low among both noncontrollers (range 1.67\u201313.57), and controllers (range 8.33\u201310) during the ATI, and remained low following it (noncontroller M = 5.07, SD = 4.52; controller M = 10.00, SD = 11.31). Participants generally understood the study, highlighted the need for partner protection support during ATI, and reported low decisional regret.<\/jats:p>","DOI":"10.1177\/08892229251375470","type":"journal-article","created":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T08:00:57Z","timestamp":1762243257000},"page":"505-516","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":4,"title":["Participant Perspectives in an HIV Treatment Interruption Study in San Francisco, United States"],"prefix":"10.1177","volume":"41","author":[{"given":"Elizabeth","family":"Nguyen","sequence":"first","affiliation":[{"name":"Division of Prevention Science, Department of Medicine, University of California, San Francisco, San Francisco, California, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anastasia","family":"Korolkova","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases and Global Public Health, Department of Medicine, University of California, San Diego, San Diego, California, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Ahmed","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases and Global Public Health, Department of Medicine, University of California, San Diego, San Diego, California, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Meanley","sequence":"additional","affiliation":[{"name":"Department of Family and Community Health, University of Pennsylvania, Philadelphia, Pennsylvania, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynda","family":"Dee","sequence":"additional","affiliation":[{"name":"AIDS Action Baltimore, Baltimore, Maryland, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryam","family":"Hussain","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases and Global Public Health, Department of Medicine, University of California, San Diego, San Diego, California, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Wan","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases and Global Public Health, Department of Medicine, University of California, San Diego, San Diego, California, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Hoh","sequence":"additional","affiliation":[{"name":"Division of HIV, Infectious Diseases and Global Medicine, Department of Medicine, University of California, San Francisco, California, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Rodriguez","sequence":"additional","affiliation":[{"name":"Division of HIV, Infectious Diseases and Global Medicine, Department of Medicine, University of California, San Francisco, California, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tony","family":"Figueroa","sequence":"additional","affiliation":[{"name":"Division of HIV, Infectious Diseases and Global Medicine, Department of Medicine, University of California, San Francisco, California, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lillian B.","family":"Cohn","sequence":"additional","affiliation":[{"name":"Fred Hutchinson Cancer Center, Seattle, Washington, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven G.","family":"Deeks","sequence":"additional","affiliation":[{"name":"Division of HIV, Infectious Diseases and Global Medicine, Department of Medicine, University of California, San Francisco, California, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Peluso","sequence":"additional","affiliation":[{"name":"Division of HIV, Infectious Diseases and Global Medicine, Department of Medicine, University of California, San Francisco, California, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shadi","family":"Eskaf","sequence":"additional","affiliation":[{"name":"Public Health Research Consultant, Chapel Hill, North Carolina, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy","family":"Sugarman","sequence":"additional","affiliation":[{"name":"Johns Hopkins Berman Institute of Bioethics, Baltimore, Maryland, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John A.","family":"Sauceda","sequence":"additional","affiliation":[{"name":"Division of Prevention Science, Department of Medicine, University of California, San Francisco, San Francisco, California, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3458-1539","authenticated-orcid":false,"given":"Karine","family":"Dub\u00e9","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases and Global Public Health, Department of Medicine, University of California, San Diego, San Diego, California, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2025,9,2]]},"reference":[{"key":"e_1_3_5_2_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01590-5"},{"key":"e_1_3_5_3_2","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms9495"},{"key":"e_1_3_5_4_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-24077-w"},{"key":"e_1_3_5_5_2","article-title":"Recommendations for analytical treatment interruptions in HIV research trials","volume":"6","author":"Julg B","year":"2019","unstructured":"Julg B, , Dee L, , Ananworanich J, et al. Recommendations for analytical treatment interruptions in HIV research trials. Report of a Consensus Meeting. Lancet HIV, 2019; 6:e259-68.","journal-title":"Report of a Consensus Meeting. Lancet HIV"},{"key":"e_1_3_5_6_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiy479"},{"key":"e_1_3_5_7_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0026-6"},{"key":"e_1_3_5_8_2","doi-asserted-by":"publisher","DOI":"10.1089\/aid.2017.0067"},{"key":"e_1_3_5_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2055-6640(20)30009-1"},{"key":"e_1_3_5_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(23)00267-0"},{"key":"e_1_3_5_11_2","first-page":"18","article-title":"Putting participants at the Centre of HIV cure research","volume":"3018","author":"Dub\u00e9 K","year":"2019","unstructured":"Dub\u00e9 K, , Barr L, , Palm D, , Brown B, , Taylor J. Putting participants at the Centre of HIV cure research. Lancet HIV, 2019; 3018:18\u201319.","journal-title":"Lancet HIV"},{"key":"e_1_3_5_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jve.2021.100029"},{"key":"e_1_3_5_13_2","doi-asserted-by":"publisher","DOI":"10.1136\/medethics-2017-104433"},{"key":"e_1_3_5_14_2","doi-asserted-by":"publisher","DOI":"10.1080\/25787489.2023.2267825"},{"key":"e_1_3_5_15_2","first-page":"1","article-title":"Participant experiences in a Combination HIV cure-related trial with extended analytical treatment interruption in San Francisco, United States","volume":"25","author":"Dub\u00e9 K","year":"2024","unstructured":"Dub\u00e9 K, , Ndukwe SO, , Korolkova A, et al. Participant experiences in a Combination HIV cure-related trial with extended analytical treatment interruption in San Francisco, United States. HIV Res & Clin Pract, 2024; 25:1\u201315.","journal-title":"HIV Res & Clin Pract"},{"key":"e_1_3_5_16_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-56116-1"},{"key":"e_1_3_5_17_2","doi-asserted-by":"publisher","DOI":"10.1089\/apc.2024.0254"},{"key":"e_1_3_5_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.socscimed.2024.117644"},{"key":"e_1_3_5_19_2","unstructured":"UCSF. PERSIST: Psychosocial and ethical aspects of HIV cure research. 2024. Available from: https:\/\/persist.ucsf.edu\/"},{"key":"e_1_3_5_20_2","unstructured":"UCSF. SCOPE: Observational study of the consequences of the protease inhibitor Era. 2020. Available from: https:\/\/clinicaltrials.ucsf.edu\/trial\/NCT00187512"},{"key":"e_1_3_5_21_2","unstructured":"ClinicalTrials.Gov. SCOPE Analytic Treatment Interruption Protocol (SCOPE-ATI). Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04359186 (2020)."},{"key":"e_1_3_5_22_2","volume-title":"IBM SPSS Statistics for Windows","author":"IBM Corp","year":"2021","unstructured":"IBM Corp. IBM SPSS Statistics for Windows. Preprint at; 2021."},{"key":"e_1_3_5_23_2","doi-asserted-by":"publisher","DOI":"10.1177\/0272989X9501500105"},{"key":"e_1_3_5_24_2","doi-asserted-by":"publisher","DOI":"10.1177\/0272989X03256005"},{"key":"e_1_3_5_25_2","doi-asserted-by":"publisher","DOI":"10.1089\/aid.2024.0086"},{"key":"e_1_3_5_26_2","unstructured":"O\u2019Connor A. User Manual - Decisional Conflict Scale. 1\u201316 1993. Available from: https:\/\/decisionaid.ohri.ca\/docs\/develop\/User_Manuals\/UM_Decisional_Conflict.pdf"},{"key":"e_1_3_5_27_2","first-page":"e25260","article-title":"Going off antiretroviral treatment in a closely monitored HIV \u2018cure\u2019 trial: Longitudinal assessments of acutely diagnosed trial participants and decliners","volume":"22","author":"Henderson GE","year":"2019","unstructured":"Henderson GE, , Waltz M, , Meagher K, et al. Going off antiretroviral treatment in a closely monitored HIV \u2018cure\u2019 trial: Longitudinal assessments of acutely diagnosed trial participants and decliners. J International, 2019; 22:e25260.","journal-title":"J International"},{"key":"e_1_3_5_28_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10461-024-04485-x"},{"key":"e_1_3_5_29_2","doi-asserted-by":"publisher","DOI":"10.1089\/aid.2021.0170"},{"key":"e_1_3_5_30_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12889-022-13528-8"},{"key":"e_1_3_5_31_2","doi-asserted-by":"publisher","DOI":"10.1089\/aid.2022.0036"},{"key":"e_1_3_5_32_2","first-page":"1","article-title":"Partner protections in HIV cure-related trials involving analytical treatment interruption: Updated toolkit to mitigate HIV transmission risk","volume":"10","author":"Dub\u00e9 K","year":"2024","unstructured":"Dub\u00e9 K, , Villa TJ, , Freshwater W, et al. Partner protections in HIV cure-related trials involving analytical treatment interruption: Updated toolkit to mitigate HIV transmission risk. J Virus Erad, 2024; 10:1\u20136.","journal-title":"J Virus Erad"},{"key":"e_1_3_5_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jve.2020.100010"},{"key":"e_1_3_5_34_2","doi-asserted-by":"publisher","DOI":"10.1089\/aid.2021.0023"}],"container-title":["AIDS Research and Human Retroviruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/08892229251375470","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/08892229251375470","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/08892229251375470","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T09:09:49Z","timestamp":1784624989000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/08892229251375470"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,2]]},"references-count":33,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,12,1]]}},"alternative-id":["10.1177\/08892229251375470"],"URL":"https:\/\/doi.org\/10.1177\/08892229251375470","relation":{},"ISSN":["0889-2229","1931-8405"],"issn-type":[{"value":"0889-2229","type":"print"},{"value":"1931-8405","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,2]]}}}